Literature DB >> 15704211

Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease.

Carsten Saft1, Jochen Zange, Jürgen Andrich, Klaus Müller, Katrin Lindenberg, Bernhard Landwehrmeyer, Matthias Vorgerd, Peter H Kraus, Horst Przuntek, Ludger Schöls.   

Abstract

Huntington's disease (HD) is an autosomal dominantly inherited neurodegenerative disorder caused by a CAG repeat expansion in the IT-15 gene; however, it remains unknown how the mutation leads to selective neurodegeneration. Several lines of evidence suggest impaired mitochondrial function as a component of the neurodegenerative process in HD. We assessed energy metabolism in the skeletal muscle of 15 HD patients and 12 asymptomatic mutation carriers in vivo using 31P magnetic resonance spectroscopy. Phosphocreatine recovery after exercise is a direct measure of ATP synthesis and was slowed significantly in HD patients and mutation carriers in comparison to age- and gender-matched healthy controls. We found that oxidative function is impaired to a similar extent in manifest HD patients and asymptomatic mutation carriers. Our findings suggest that mitochondrial dysfunction is an early and persistent component of the pathophysiology of HD. (c) 2004 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15704211     DOI: 10.1002/mds.20373

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  76 in total

1.  Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.

Authors:  Rajnish K Chaturvedi; Noel Y Calingasan; Lichuan Yang; Thomas Hennessey; Ashu Johri; M Flint Beal
Journal:  Hum Mol Genet       Date:  2010-06-07       Impact factor: 6.150

Review 2.  Brain networks in Huntington disease.

Authors:  David Eidelberg; D James Surmeier
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

Review 3.  Energy deficit in Huntington disease: why it matters.

Authors:  Fanny Mochel; Ronald G Haller
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

4.  Circadian dysfunction in the Q175 model of Huntington's disease: Network analysis.

Authors:  Benjamin Smarr; Tamara Cutler; Dawn H Loh; Takashi Kudo; Dika Kuljis; Lance Kriegsfeld; Cristina A Ghiani; Christopher S Colwell
Journal:  J Neurosci Res       Date:  2019-07-29       Impact factor: 4.164

Review 5.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body.

Authors:  Bronwen Martin; Erin Golden; Alex Keselman; Matthew Stone; Mark P Mattson; Josephine M Egan; Stuart Maudsley
Journal:  Histol Histopathol       Date:  2008-02       Impact factor: 2.303

Review 6.  Mutant huntingtin and mitochondrial dysfunction.

Authors:  Ella Bossy-Wetzel; Alejandra Petrilli; Andrew B Knott
Journal:  Trends Neurosci       Date:  2008-10-24       Impact factor: 13.837

7.  Upper gastrointestinal findings in Huntington's disease: patients suffer but do not complain.

Authors:  Jürgen E Andrich; Michael Wobben; Peter Klotz; Oliver Goetze; Carsten Saft
Journal:  J Neural Transm (Vienna)       Date:  2009-09-22       Impact factor: 3.575

8.  Abnormal morphology of peripheral cell tissues from patients with Huntington disease.

Authors:  Ferdinando Squitieri; Alessandra Falleni; Milena Cannella; Sara Orobello; Federica Fulceri; Paola Lenzi; Francesco Fornai
Journal:  J Neural Transm (Vienna)       Date:  2009-10-16       Impact factor: 3.575

Review 9.  Chipping away at diagnostics for neurodegenerative diseases.

Authors:  Clemens R Scherzer
Journal:  Neurobiol Dis       Date:  2009-03-10       Impact factor: 5.996

10.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.